Despite the availability of effective antibiotics, TB is the leading worldwide killer. While current drugs work, they are far from optimal. Therapy is lengthy. Patients who stop treatment before six months have a significant risk of relapse even though their symptoms subside months earlier.
The TB Structural Genomics Consortium (TBSGC) started fifteen years ago as an effort to produce a diverse set of mycobacterial protein structures . However, since that time, our goals have evolved. Instead of emphasizing the numbers of structures solved, we have moved to focusing on proteins that could be potential antibiotic targets.